Intellia Therapeutics Announces Third Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Intellia Therapeutics (NTLA) PT Raised to $39 at Raymond James
November 5, 2020 12:52 PM ESTRaymond James analyst Steven Seedhouse raised the price target on Intellia Therapeutics (NASDAQ: NTLA) to $39.00 (from $27.00) while maintaining a Outperform rating.
... MoreIntellia Therapeutics (NTLA) Tops Q3 EPS by 12c, Revenues Beat
November 5, 2020 8:13 AM ESTIntellia Therapeutics (NASDAQ: NTLA) reported Q3 EPS of ($0.47), $0.12 better than the analyst estimate of ($0.59). Revenue for the quarter came in at $22.22 million versus the consensus estimate of $15.58 million.
We are very pleased with the recent regulatory... More
